N
ADVM

Nuveen’s Adverum Biotechnologies ADVM Stock Holding History

Nuveen’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,847
Closed -$139K – 3277
2025
Q1 		$139K Sell
31,847
-140,590
-82% -$634K ﹤0.01% 3175
2024
Q4 		$805K Sell
172,437
-1,240
-0.7% -$8.35K ﹤0.01% 2798
2024
Q3 		$1.22M Buy
173,677
+105,140
+153% +$763K ﹤0.01% 2670
2024
Q2 		$470K Buy
+68,537
New +$637K ﹤0.01% 3016
2022
Q2 		– Sell
-34,312
Closed -$3.49M – 3231
2022
Q1 		$3.49M Buy
34,312
+66
+0.2% +$966 ﹤0.01% 2252
2021
Q4 		$3.48M Sell
34,246
-2,858
-8% -$57.2K ﹤0.01% 2299
2021
Q3 		$3.77M Sell
37,104
-10,403
-22% -$265K ﹤0.01% 2361
2021
Q2 		$4.83M Buy
47,507
+4,657
+11% +$251K ﹤0.01% 2269
2021
Q1 		$4.22M Buy
42,850
+3,127
+8% +$375K ﹤0.01% 2243
2020
Q4 		$4.31M Buy
39,723
+122
+0.3% +$15.1K ﹤0.01% 2148
2020
Q3 		$4.08M Buy
39,601
+4,033
+11% +$604K ﹤0.01% 2031
2020
Q2 		$7.43M Buy
35,568
+10,840
+44% +$1.92M ﹤0.01% 1681
2020
Q1 		$2.42M Buy
24,728
+3,197
+15% +$373K ﹤0.01% 2096
2019
Q4 		$2.48M Buy
21,531
+416
+2% +$36.7K ﹤0.01% 2333
2019
Q3 		$1.15M Sell
21,115
-401
-2% -$45.2K ﹤0.01% 2641
2019
Q2 		$2.56M Buy
+21,516
New +$1.78M ﹤0.01% 2313

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen's ADVM Position: Q2 2025 in Review

Nuveen sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 31,847 shares — an estimated $139K sold.

Nuveen first reported a position in ADVM in Q2 2019 and held it in 16 quarters. The position peaked at $7.43M in Q2 2020. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.

  • Nuveen reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 31,847 Adverum Biotechnologies shares in Q2 2025, an estimated $139K.
  • Nuveen first reported a position in Adverum Biotechnologies in Q2 2019 and held it in 16 quarters.
  • Nuveen's Adverum Biotechnologies position peaked at $7.43M in Q2 2020.
  • 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.